Papers
3
Total Citations
45
H-Index
3
About
Dr. Sarah Neufeld is a radiation oncologist whose research centers on stereotactic partial breast irradiation (S-PBI) for early-stage breast cancer. Her major contributions involve pioneering dose-escalation protocols to optimize treatment precision while minimizing toxicity. In her multi-institutional Phase 1 trial, she demonstrated the safety and feasibility of single-fraction S-PBI after partial mastectomy, a technique that compresses weeks of conventional radiation into a single, highly targeted dose. Her work on 5-fraction regimens further refined cosmetic outcomes, showing that accelerated, hypofractionated approaches can preserve breast appearance without compromising tumor control. With her most-cited paper accumulating 23 citations, Neufeld’s research has directly shaped clinical guidelines for partial breast irradiation. Notably, her phase 1 dose-escalation study—enrolling patients with stage 0–II disease—represents one of the first prospective, multicenter efforts to establish maximum tolerated doses for robotic stereotactic systems. By systematically evaluating both efficacy and patient-reported cosmetic results, she has advanced a paradigm shift toward shorter, more convenient radiation schedules. Her findings continue to inform ongoing phase 2/3 trials, positioning her as a key investigator in de-escalating breast cancer treatment.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3